These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16299001)

  • 1. Estrogen receptor-alpha mediates gender differences in atherosclerosis induced by HIV protease inhibitors.
    Allred KF; Smart EJ; Wilson ME
    J Biol Chem; 2006 Jan; 281(3):1419-25. PubMed ID: 16299001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleoside reverse transcriptase inhibitors prevent HIV protease inhibitor-induced atherosclerosis by ubiquitination and degradation of protein kinase C.
    Bradshaw EL; Li XA; Guerin T; Everson WV; Wilson ME; Bruce-Keller AJ; Greenberg RN; Guo L; Ross SA; Smart EJ
    Am J Physiol Cell Physiol; 2006 Dec; 291(6):C1271-8. PubMed ID: 16822947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir.
    Wilson ME; Sengoku T; Allred KF
    J Cell Biochem; 2008 Apr; 103(5):1598-606. PubMed ID: 17879945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice.
    Mencarelli A; Cipriani S; Renga B; Francisci D; Palladino G; Distrutti E; Baldelli F; Fiorucci S
    PLoS One; 2010 Oct; 5(10):e13238. PubMed ID: 20949026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acipimox, an inhibitor of lipolysis, attenuates atherogenesis in LDLR-null mice treated with HIV protease inhibitor ritonavir.
    Guo W; Wong S; Pudney J; Jasuja R; Hua N; Jiang L; Miller A; Hruz PW; Hamilton JA; Bhasin S
    Arterioscler Thromb Vasc Biol; 2009 Dec; 29(12):2028-32. PubMed ID: 19762785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages.
    Dressman J; Kincer J; Matveev SV; Guo L; Greenberg RN; Guerin T; Meade D; Li XA; Zhu W; Uittenbogaard A; Wilson ME; Smart EJ
    J Clin Invest; 2003 Feb; 111(3):389-97. PubMed ID: 12569165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pregnane X receptor mediates dyslipidemia induced by the HIV protease inhibitor amprenavir in mice.
    Helsley RN; Sui Y; Ai N; Park SH; Welsh WJ; Zhou C
    Mol Pharmacol; 2013 Jun; 83(6):1190-9. PubMed ID: 23519392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
    Arvieux C; Tribut O
    Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haloperidol inhibits the development of atherosclerotic lesions in LDL receptor knockout mice.
    van der Sluis RJ; Nahon JE; Reuwer AQ; Van Eck M; Hoekstra M
    Br J Pharmacol; 2015 May; 172(9):2397-405. PubMed ID: 25572138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Babaev VR; Ishiguro H; Ding L; Yancey PG; Dove DE; Kovacs WJ; Semenkovich CF; Fazio S; Linton MF
    Circulation; 2007 Sep; 116(12):1404-12. PubMed ID: 17724261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid cell-specific ATP-binding cassette transporter A1 deletion has minimal impact on atherogenesis in atherogenic diet-fed low-density lipoprotein receptor knockout mice.
    Bi X; Zhu X; Gao C; Shewale S; Cao Q; Liu M; Boudyguina E; Gebre AK; Wilson MD; Brown AL; Parks JS
    Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):1888-99. PubMed ID: 24833800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophage sortilin promotes LDL uptake, foam cell formation, and atherosclerosis.
    Patel KM; Strong A; Tohyama J; Jin X; Morales CR; Billheimer J; Millar J; Kruth H; Rader DJ
    Circ Res; 2015 Feb; 116(5):789-96. PubMed ID: 25593281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in dietary omega-6 polyunsaturated fatty acids: eicosapentaenoic acid plus docosahexaenoic acid ratio minimizes atherosclerotic lesion formation and inflammatory response in the LDL receptor null mouse.
    Wang S; Wu D; Matthan NR; Lamon-Fava S; Lecker JL; Lichtenstein AH
    Atherosclerosis; 2009 May; 204(1):147-55. PubMed ID: 18842266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis.
    Rahtu-Korpela L; Määttä J; Dimova EY; Hörkkö S; Gylling H; Walkinshaw G; Hakkola J; Kivirikko KI; Myllyharju J; Serpi R; Koivunen P
    Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):608-17. PubMed ID: 26848160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients.
    Goujard C; Vincent I; Meynard JL; Choudet N; Bollens D; Rousseau C; Demarles D; Gillotin C; Bidault R; Taburet AM
    Antimicrob Agents Chemother; 2003 Jan; 47(1):118-23. PubMed ID: 12499178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Accelerates Atherosclerosis Regression and Increases C-C Chemokine Receptor Type 7 (CCR7) Expression in Plaque Macrophages.
    Mueller PA; Zhu L; Tavori H; Huynh K; Giunzioni I; Stafford JM; Linton MF; Fazio S
    Circulation; 2018 Oct; 138(17):1850-1863. PubMed ID: 29794082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes.
    Zhou H; Gurley EC; Jarujaron S; Ding H; Fang Y; Xu Z; Pandak WM; Hylemon PB
    Am J Physiol Gastrointest Liver Physiol; 2006 Dec; 291(6):G1071-80. PubMed ID: 16861219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α
    Szpak D; Izem L; Verbovetskiy D; Soloviev DA; Yakubenko VP; Pluskota E
    J Immunol; 2018 Apr; 200(7):2426-2438. PubMed ID: 29459405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
    Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of oxLDL uptake leads to decreased atherosclerosis in hematopoietic NPC1-deficient Ldlr
    Jeurissen MLJ; Walenbergh SMA; Houben T; Gijbels MJJ; Li J; Hendrikx T; Oligschlaeger Y; van Gorp PJ; Binder CJ; Donners MMPC; Shiri-Sverdlov R
    Atherosclerosis; 2016 Dec; 255():59-65. PubMed ID: 27816810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.